author-photo

Suryavathi Viswanadhapalli

University of Texas Health Science Center at San Antonio
University of Texas at Austin

85

Papers

583

Citations

Citation Trend

Filter By

Papers (51) Sort By

Journal Conference Others

KDM1A inhibition augments the efficacy of rapamycin for the treatment of endometrial cancer.

2022 Cancer Letters
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS17-09: Development of a potent mutant-ESR1 targeted agent, ERX-245, for treating metastatic therapy-resistant breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 2026: KDM1A inhibition augment ER stress inducers efficacy to reduce glioblastoma stemness

2021
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS17-15: Targeting the PELP1 axis for treating ESR1 mutant driven breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1333: Evaluation of a novel PELP1 inhibitor for treatment of triple negative breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1253: Therapeutic targeting of endometrial cancer with novel LIFR inhibitor EC359

2021
Show All
- Source
- Cite
- Save
Citations (0)
Targeting LIF/LIFR signaling in cancer

2021 Genes and Diseases
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS17-34: Proto-oncogene PELP1 interactions with SETDB1 contribute to aberrant activation of AKT1 in breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS19-14: Matrin3 inhibits breast cancer growth by suppressing microtubule nucleation protein MZT2B

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.

2021 Cell death discovery
Show All
- Source
- Cite
- Save
Citations (1)